Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Assets Average (2022 - 2025)

BioXcel Therapeutics has reported Assets Average over the past 4 years, most recently at $44.9 million for Q4 2025.

  • Quarterly results put Assets Average at $44.9 million for Q4 2025, up 2.84% from a year ago — trailing twelve months through Dec 2025 was $44.9 million (up 2.84% YoY), and the annual figure for FY2025 was $41.6 million, down 25.69%.
  • Assets Average for Q4 2025 was $44.9 million at BioXcel Therapeutics, up from $35.3 million in the prior quarter.
  • Over the last five years, Assets Average for BTAI hit a ceiling of $246.5 million in Q3 2022 and a floor of $32.2 million in Q2 2025.
  • Median Assets Average over the past 4 years was $78.0 million (2024), compared with a mean of $111.0 million.
  • Biggest five-year swings in Assets Average: tumbled 61.36% in 2023 and later rose 2.84% in 2025.
  • BioXcel Therapeutics' Assets Average stood at $225.3 million in 2022, then tumbled by 61.36% to $87.1 million in 2023, then plummeted by 49.91% to $43.6 million in 2024, then rose by 2.84% to $44.9 million in 2025.
  • The last three reported values for Assets Average were $44.9 million (Q4 2025), $35.3 million (Q3 2025), and $32.2 million (Q2 2025) per Business Quant data.